Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.
Researched for: PepTools vendor-neutral scientific reference catalog
Also known as: phentermine and topiramate, phentermine/topiramate extended-release, phentermine hydrochloride/topiramate, Qsymia, Qnexa
Phentermine/topiramate is a fixed-dose oral combination formulation rather than a single covalent molecular entity. The approved extended-release capsule contains immediate-release phentermine hydrochloride and extended-release topiramate in four strength combinations: 3.75/23 mg, 7.5/46 mg, 11.25/69 mg, and 15/92 mg. The labeled indication includes adults with obesity, adults with overweight plus at least one weight-related comorbidity, and, in current U.S. labeling, pediatric patients aged 12 years and older with obesity.
Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.
Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
Neutral study/reference regimen information: the CONQUER phase 3 trial evaluated once-daily oral phentermine 7.5 mg plus topiramate 46 mg and phentermine 15 mg plus topiramate 92 mg for 56 weeks in adults with BMI 27-45 kg/m² and at least two specified comorbidities. The U.S. label describes a 3.75/23 mg starting strength followed by 7.5/46 mg, with optional escalation through 11.25/69 mg to 15/92 mg based on response; this is recorded as regulatory reference information, not individualized treatment guidance. The 15/92 mg regimen requires gradual discontinuation in the label because of seizure risk associated with abrupt topiramate withdrawal.
Supplementary research context only. Not medical advice or a treatment recommendation.
PubChem CID 56842108; CAS 960078-81-3; aggregate molecular formula C22H36N2O8S; aggregate molecular weight 488.6 g/mol; PubChem InChIKey PWDLDBWXTVILPC-QGGVPXFVSA-N. Identity represents the phentermine/topiramate combination record and should not be interpreted as a single covalent molecule.
The combination has distinct pharmacologic components with different release characteristics and pharmacokinetics. Phentermine is a Schedule IV controlled substance in the United States; topiramate is not controlled under the cited label. The exact mechanism of weight reduction for the combination is not fully established. Label-described mechanisms include catecholamine release and reduced appetite for phentermine, while proposed topiramate-related effects include appetite suppression and enhanced satiety.
Reflects published research. Educational reference — not a recommendation for use.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.